ICD-11 code 1F86.1 refers to schistosomiasis due to Schistosoma mansoni, a parasitic infection caused by a particular species of flatworm. This specific code is used for clinical documentation and data collection purposes to classify cases of the disease caused by this particular parasite.
Schistosomiasis is a neglected tropical disease spread through contaminated water sources in parts of Africa, South America, the Middle East, and Asia. The Schistosoma mansoni parasite enters the human body through the skin during contact with infested water and causes a range of symptoms including abdominal pain, diarrhea, and liver damage.
The use of ICD-11 code 1F86.1 allows for accurate tracking of cases of schistosomiasis caused by Schistosoma mansoni, aiding in public health efforts to monitor and control the spread of this parasitic infection. This particular code ensures that healthcare providers can effectively document and report cases of schistosomiasis due to this specific species of parasite for surveillance and treatment purposes.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The equivalent SNOMED CT code for the ICD-11 code 1F86.1, which represents Schistosomiasis due to Schistosoma mansoni, is 77243006. This code in the SNOMED CT terminology database specifically denotes infection caused by Schistosoma mansoni, a parasitic flatworm that is commonly found in Africa, the Middle East, and parts of South America. The SNOMED CT code 77243006 provides a detailed and standardized way to classify and code cases of Schistosomiasis due to Schistosoma mansoni, allowing for accurate and consistent documentation of this particular type of infection across healthcare systems and institutions. This coding system ensures that healthcare professionals can easily identify, track, and treat cases of Schistosomiasis due to Schistosoma mansoni with precision and efficiency.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Symptoms of 1F86.1 (Schistosomiasis due to Schistosoma mansoni) typically manifest in two phases: the acute phase and the chronic phase. In the acute phase, which occurs shortly after infection, individuals may experience fever, chills, cough, and abdominal pain. Some may also develop a rash, muscle aches, and diarrhea.
As the disease progresses to the chronic phase, symptoms may become more severe. Chronic schistosomiasis due to Schistosoma mansoni is characterized by intestinal and hepatosplenic involvement. Individuals may experience symptoms such as bloody diarrhea, hepatomegaly, splenomegaly, and ascites. In some cases, the chronic phase of the disease can lead to life-threatening complications such as liver failure and portal hypertension.
In addition to gastrointestinal and hepatic symptoms, individuals with 1F86.1 may also experience genitourinary manifestations. Schistosoma mansoni eggs can become lodged in the bladder or ureters, leading to symptoms such as hematuria, dysuria, and urinary tract infections. In severe cases, chronic infection with Schistosoma mansoni can result in kidney damage and renal failure. Overall, the symptoms of 1F86.1 can range from mild to severe, depending on the duration and intensity of the infection.
🩺 Diagnosis
Diagnosis of 1F86.1 (Schistosomiasis due to Schistosoma mansoni) typically involves a combination of clinical assessment, laboratory testing, and imaging studies. Clinical symptoms commonly include fever, fatigue, abdominal pain, diarrhea, and blood in the urine. These symptoms may vary depending on the stage of the infection and the individual’s immune response.
Laboratory tests play a crucial role in diagnosing Schistosoma mansoni infection. Blood tests can detect antibodies to the parasite or specific antigens produced by the parasite. Stool or urine samples can also be examined for the presence of parasite eggs. In some cases, a biopsy of affected tissues may be necessary to confirm the diagnosis.
Imaging studies, such as ultrasound or computed tomography (CT) scans, can help visualize the extent of organ damage caused by Schistosoma mansoni infection. These imaging tests are particularly valuable in assessing complications such as liver fibrosis, portal hypertension, or bladder obstruction. Additionally, imaging studies can aid in monitoring the effectiveness of treatment and evaluating disease progression over time.
💊 Treatment & Recovery
Treatment options for 1F86.1 (Schistosomiasis due to Schistosoma mansoni) typically involve the use of medication to eliminate the parasitic infection. The primary drug of choice for treating this particular type of schistosomiasis is praziquantel, which is known to be effective in killing the adult worms responsible for the infection. It is typically administered in a single dose, making it a convenient treatment option for patients.
In addition to medication, supportive care may also be necessary to manage symptoms and complications associated with schistosomiasis. This may include addressing issues such as anemia, liver enlargement, and other health problems caused by the infection. Patients may also require additional treatment for related conditions, such as bacterial infections or gastrointestinal issues.
Recovery from Schistosoma mansoni infection can vary depending on the severity of the infection and the individual’s overall health. In many cases, treatment with praziquantel is highly effective in eliminating the infection and allowing for a full recovery. However, some patients may experience lingering symptoms or complications that require ongoing medical care. It is important for patients to follow their healthcare provider’s recommendations for follow-up care and monitoring to ensure a successful recovery.
🌎 Prevalence & Risk
In the United States, Schistosoma mansoni is not endemic and cases are usually seen in individuals who have traveled to areas where the parasite is prevalent. The prevalence of 1F86.1 in the United States is therefore relatively low compared to regions where the disease is endemic. Cases are often reported in travelers returning from sub-Saharan Africa or other regions where Schistosoma mansoni is commonly found.
In Europe, Schistosoma mansoni is also not endemic, but sporadic cases have been reported in travelers returning from endemic areas. The prevalence of 1F86.1 in Europe is generally low, with most cases being imported from regions with high endemicity. Public health measures are in place to prevent the establishment of the parasite in Europe, and cases are usually promptly treated to prevent transmission.
In Asia, Schistosoma mansoni is not as common as other species of Schistosoma, such as Schistosoma japonicum in the Philippines and China. The prevalence of 1F86.1 in Asia is therefore relatively low compared to other regions where different species of Schistosoma are endemic. Travelers to endemic areas should take precautions to prevent infection and seek medical attention if they develop symptoms of schistosomiasis.
In Africa, Schistosoma mansoni is endemic in many countries, particularly in sub-Saharan Africa. The prevalence of 1F86.1 in Africa is high, with millions of people affected by the disease. Control measures, such as mass drug administration and improved sanitation, have been implemented in endemic areas to reduce the burden of schistosomiasis. Efforts are ongoing to eliminate the parasite and reduce the prevalence of 1F86.1 in Africa.
😷 Prevention
Preventing 1F86.1, also known as Schistosomiasis due to Schistosoma mansoni, involves various measures to control the spread of the disease. One important aspect of prevention is to avoid contact with contaminated water sources where the parasite-carrying snails reside. This includes avoiding swimming or bathing in freshwater lakes, rivers, or streams in endemic areas where Schistosomiasis is prevalent.
In addition to avoiding contact with contaminated water, it is also essential to practice good hygiene to prevent the spread of the disease. This includes washing hands frequently with soap and water, especially before eating or preparing food. It is also important to properly dispose of human waste to prevent contamination of the environment with Schistosoma mansoni eggs, which can infect snails and perpetuate the life cycle of the parasite.
Furthermore, preventive measures may also include deworming treatments for individuals living in endemic areas. Mass drug administration programs may be implemented to treat entire populations at risk of Schistosomiasis, which can help reduce the overall burden of disease in affected communities. Education and awareness campaigns about the causes, transmission, and prevention of Schistosomiasis can also play a crucial role in reducing the incidence of 1F86.1 in endemic regions.
🦠 Similar Diseases
One disease similar to 1F86.1 is schistosomiasis caused by Schistosoma japonicum. This disease is also a type of parasitic infection that affects humans, particularly in areas with poor sanitation and water quality. The main difference between Schistosoma japonicum and Schistosoma mansoni is the geographical distribution, as the former is more common in certain parts of Asia.
Another related disease is schistosomiasis caused by Schistosoma haematobium. Like Schistosoma mansoni, this parasite can infect humans through contaminated water sources. However, Schistosoma haematobium primarily affects the urinary tract, leading to symptoms such as hematuria and dysuria. This disease is most prevalent in parts of Africa and the Middle East.
Additionally, schistosomiasis caused by Schistosoma intercalatum is another disease that is similar to 1F86.1. This parasite primarily infects humans in West and Central Africa, leading to symptoms such as abdominal pain and diarrhea. Schistosoma intercalatum is less common compared to other species of Schistosoma, but it can still have significant impacts on affected populations.
Overall, schistosomiasis is a group of diseases caused by different species of Schistosoma parasites, each with its own unique characteristics and geographical distribution. While Schistosoma mansoni is a common cause of schistosomiasis in certain regions, other species such as Schistosoma japonicum, Schistosoma haematobium, and Schistosoma intercalatum can also lead to similar clinical manifestations in infected individuals. Understanding the differences between these diseases is crucial for accurate diagnosis and treatment of schistosomiasis worldwide.